Piper Sandler Issues Positive Forecast for Edwards Lifesciences (NYSE:EW) Stock Price

Edwards Lifesciences (NYSE:EW) had its price objective boosted by Piper Sandler from $70.00 to $73.00 in a research note issued to investors on Wednesday morning,Benzinga reports. They currently have a neutral rating on the medical research company’s stock.

A number of other research firms also recently commented on EW. JPMorgan Chase & Co. raised their target price on Edwards Lifesciences from $72.00 to $78.00 and gave the company a “neutral” rating in a report on Friday, October 25th. Robert W. Baird lowered their target price on Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating on the stock in a report on Friday, October 25th. Canaccord Genuity Group lifted their price objective on Edwards Lifesciences from $63.00 to $68.00 and gave the stock a “hold” rating in a research report on Thursday, December 5th. Wolfe Research lowered shares of Edwards Lifesciences from a “peer perform” rating to an “underperform” rating and set a $60.00 target price on the stock. in a report on Thursday, January 16th. Finally, Royal Bank of Canada boosted their price target on Edwards Lifesciences from $80.00 to $85.00 and gave the company an “outperform” rating in a report on Thursday, December 5th. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $79.71.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock opened at $75.83 on Wednesday. The firm’s fifty day simple moving average is $72.47 and its 200-day simple moving average is $69.32. Edwards Lifesciences has a 12 month low of $58.93 and a 12 month high of $96.12. The stock has a market capitalization of $44.72 billion, a price-to-earnings ratio of 10.94, a PEG ratio of 3.64 and a beta of 1.10. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, beating analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. As a group, equities analysts forecast that Edwards Lifesciences will post 2.56 earnings per share for the current year.

Insiders Place Their Bets

In other news, VP Daniel J. Lippis sold 500 shares of the firm’s stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total transaction of $34,380.00. Following the completion of the sale, the vice president now owns 23,189 shares of the company’s stock, valued at approximately $1,594,475.64. This trade represents a 2.11 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.29% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in EW. Crowley Wealth Management Inc. bought a new stake in shares of Edwards Lifesciences in the 4th quarter worth about $26,000. Millstone Evans Group LLC acquired a new position in Edwards Lifesciences in the fourth quarter worth about $29,000. Migdal Insurance & Financial Holdings Ltd. bought a new stake in Edwards Lifesciences in the fourth quarter valued at about $30,000. FSA Wealth Management LLC acquired a new stake in Edwards Lifesciences during the third quarter valued at approximately $30,000. Finally, Prospera Private Wealth LLC bought a new position in Edwards Lifesciences during the 3rd quarter worth approximately $32,000. 79.46% of the stock is currently owned by institutional investors.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.